Long-term safety and effectiveness of lopinavir/ritonavir in antiretroviral-experienced HIV-1-infected children.
| Data(s) |
2010
|
|---|---|
| Resumo |
AIM: To evaluate the long-term safety and effectiveness of lopinavir/ritonavir (LPV/r) in a population-based cohort of HIV-1-infected children. METHODS: All children enrolled in the Swiss Mother and Child HIV Cohort Study, treated with LPV/r-based combination antiretroviral treatment (cART) between November 2000 and October 2008, were included. RESULTS: 88 children (25 (28%) protease inhibitor (PI)-naive, 16 (18%) ART-naive) were analysed (251 patient-years on LPV/r). After 48 weeks on LPV/r, 70 children had a median (interquartile range (IQR)) decrease in HIV-1 viral load of 4.25 log (5.45-3.17; PI-naive, n=17) and 2.53 (3.68-1.38; PI-experienced, n=53). Median (IQR) increase in CD4 count was 429 (203-593; PI-naive) and 177 (21-331; PI-experienced) cells/microl. These effects remained stable throughout 192 weeks for 25 children. Treatment was stopped for viral rebound in seven and suspected toxicity in 12 children. CONCLUSION: Long-term treatment with LPV/r-based cART is safe and effective in HIV-1-infected children. |
| Identificador |
https://serval.unil.ch/?id=serval:BIB_5E884C0CA0D9 isbn:1468-2044 (Electronic) pmid:20501542 doi:10.1136/adc.2009.169375 isiid:000278002000016 |
| Idioma(s) |
en |
| Fonte |
Archives of Disease In Childhood, vol. 95, no. 6, pp. 478-481 |
| Palavras-Chave | #Adolescent; CD4 Lymphocyte Count; Child; Child, Preschool; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections/drug therapy; HIV Infections/immunology; HIV Protease Inhibitors/adverse effects; HIV Protease Inhibitors/therapeutic use; HIV-1/isolation & purification; Humans; Lopinavir; Male; Prospective Studies; Pyrimidinones/adverse effects; Pyrimidinones/therapeutic use; Ritonavir/adverse effects; Ritonavir/therapeutic use; Treatment Outcome; Viral Load |
| Tipo |
info:eu-repo/semantics/article article |
